essential thrombocytosis

I'm your host today, Chris Ryan.

In today's episode, we welcome Dr. Ruben Mesa, who outlined the significance of the August 2026 FDA approval of Ropeg interferon alpha-2b for the treatment of adult patients with essential thrombocythemia.

Dr. Mesa is the Senior Vice President of Atrium Health and President and Executive Director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Charlotte, North Carolina.

In the exclusive interview, Dr. Mason discussed what the FDA approval of Ropeg interferon-alpha-2b means for the essential thrombocythemia treatment paradigm, detailed the key efficacy and safety findings from the Phase III SURPASS-ET trial that supported the approval, and looked ahead to other research that could continue to affect this treatment paradigm.

Thank you again, Dr. Mesa, for joining us today for discussing exciting approval within the ET space.

So I just wanted to get us started looking at essential thrombocythemia as a whole.

I know it's been almost 30 years since the FDA approved an agent for the treatment of this patient population.

So just what has been the unmet need and the drive to deliver more treatment options for this patient population?

Thanks, Pharma Essentia.

Kate, it's been a fantastic season learning more about ET and digging in deeper on PV.

I'm always so impressed by our guests and the conversations just keep getting better.

What do we have on the slate today?

And then I'm able to really connect with them at the first treatment.

And so that's how my practice is here.

But I would say for anyone who's going through a diagnosis of PV or ET, there's not, really a right or wrong time.

I would say my biggest advice is not to wait for a crisis.